Menu Search
Equities

Crescita Therapeutics Inc

CTX:TOR

Crescita Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.62
  • Today's Change0.03 / 5.08%
  • Shares traded14.37k
  • 1 Year change-4.62%
  • Beta1.7070
Data delayed at least 15 minutes, as of Sep 20 2024 19:45 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year Crescita Therapeutics Inc's revenues fell -25.52% from 23.53m to 17.52m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 862.00k to a loss of 1.99m.
Gross margin54.66%
Net profit margin-17.72%
Operating margin-16.77%
Return on assets-12.06%
Return on equity-15.79%
Return on investment-15.07%
More ▼

Cash flow in CADView more

In 2023, Crescita Therapeutics Inc increased its cash reserves by 13.92%, or 1.15m. The company earned 2.08m from its operations for a Cash Flow Margin of 11.85%. In addition the company used 133.00k on investing activities and also paid 782.00k in financing cash flows.
Cash flow per share-0.0775
Price/Cash flow per share--
Book value per share0.8861
Tangible book value per share0.7813
More ▼

Balance sheet in CADView more

Crescita Therapeutics Inc appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.82% of the market capitalization can be attributed to its 9.39m and debt could be paid in full if management chose.
Current ratio3.37
Quick ratio2.32
Total debt/total equity0.0603
Total debt/total capital0.0568
More ▼

Growth rates in CAD

Year on year, growth in earnings per share excluding extraordinary items dropped -338.86%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-510.59
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.